Indian pharma market grows 13.3% in June; Monthly sales cross Rs 21,400 Cr: Pharmarack

image credit- freepik

The Indian Pharmaceutical Market (IPM) continued its strong growth trajectory in June 2026, recording sales of Rs 21,478 crore, a 13.3 per cent value growth over June 2025, according to the latest data from Pharmarack Technologies. Unit sales also grew 2.3 per cent, indicating that growth was supported by both higher volumes and improved product mix.

The June performance was significantly stronger than the market's 9.8 per cent value growth recorded for the moving annual total (MAT), reinforcing the sustained momentum seen across the industry during the first half of 2026. According to data from Pharmarack Technologies, all therapy segments registered positive value growth during the month, reflecting broad-based demand across chronic, acute and specialty therapies.

Sharing insights on the market, Sheetal Sapale, Vice President – Commercial at Pharmarack Technologies, said, "The IPM has shown a value growth of 13.3 per cent with all the therapies showing positive value growth. Anti-Neoplastics and Vaccines are showing double-digit growth in both value and units."

Cardiac therapies retained their position as the largest therapy segment, contributing 14 per cent of the market with sales of Rs 3,090 crore in June, registering a robust 16.1 per cent value growth and 5.8 per cent unit growth. Anti-diabetic therapies continued their strong momentum, growing 18.8 per cent to Rs 2,085 crore, while Nutritionals (Vitamins, Minerals and Nutrition) expanded 16.3 per cent to Rs 2,047 crore, supported by a healthy 6.8 per cent increase in unit sales. Among the high-volume therapies, Anti-Infectives reported sales of Rs 2,211 crore, growing 9.0 per cent, while Gastrointestinal therapies increased 8.3 per cent to Rs 2,641 crore. Respiratory therapies maintained double-digit momentum with 12.8 per cent value growth to Rs 1,334 crore, driven by a 9.0 per cent increase in unit sales.

Pain and Analgesics recorded sales of Rs 1,486 crore, growing 11.2 per cent, while Neuro/CNS therapies expanded 14.8 per cent to Rs 1,457 crore. Dermatology also remained resilient with 12.7 per cent growth, reaching Rs 1,387 crore. Among specialty therapies, Vaccines emerged as the fastest-growing category during the month, posting 17.2 per cent value growth and 16.5 per cent unit growth, taking monthly sales to Rs 211 crore. Anti-Neoplastics also delivered strong performance with 16.7 per cent value growth and 10.0 per cent unit growth, reflecting sustained demand for oncology therapies.

Urology continued to outperform the broader market, registering 19.3 per cent value growth to Rs 407 crore, while Blood-related therapies grew 13.6 per cent and Gynaecological products recorded 13.1 per cent growth during the month.  Other therapy segments also reported healthy gains. Stomatologicals expanded 13.1 per cent, Sex Stimulants/Rejuvenation products grew 10.8 per cent, Ophthalmology/Otologicals increased 8.2 per cent, and Hormones recorded 7.5 per cent growth.

Narayan Kulkarni

Narayan.kulkarni@mmactiv.com